Motif Bio Share Discussion Threads

[bi11y ray va1entine] 03/2/2021 15:53

That's kind of my point Scott. Why are you relying on the Motif board to explain something that anybody who's familiar with patent law could answer? You wouldn't email the company demanding they offer you an organic chemistry PhD course because they have a duty to educate you on the mechanisms of gram-positive antibiotics, or else they don't deserve to receive their salaries. So where do you draw the line?

[scottdavid70] 03/2/2021 14:20

How does Sandoz have a patent on something Hercules owns? Explain

[bi11y ray va1entine] 03/2/2021 13:35

Your best bet is to speak to an IP lawyer or do some research if you have a general question regarding another company's patents Scott. If you were unclear about the implications of the Sandoz patent we could've discussed it when I first drew your attention to it.

[scottdavid70] 03/2/2021 03:13

If Mitif Bio don’t explain EXACTLY what is happening with Iclaprim and the potential RTO along with the vote i for one will not vote this through.

The contract and upside potential needs to be explained in black and white.

Was Iclaprim a total white elector Lumsden and his co-conspirators to snaffle their huge salaries?

What is the situation of the patents with Sandoz?

What upside for investors if a RTO happens and Iclaprim gets sold post RTO?

Total utter clarity for once or I won’t be voting this through not will many others

[chuffer2] 01/2/2021 12:36

Who cares now.
It will just be by the bod looking after themselves looking for a huge playoff in the form of redundancy or basic wage plus bonus if kept on.
There will be zero consideration for motifbio shareholders, that l can guarantee.

[rfcmoore66] 01/2/2021 10:59

So now it's February what are the legal and regulatory timeframes?

[jibba jabber] 01/2/2021 10:50

Even scottdavid has given up!

[wooste] 27/1/2021 16:37

what's your prediction moneymunch….I don't have much faith left either

[perfectstorm] 27/1/2021 13:43

The RNS just gives false hope where there is none. if you read it properly it is just a load of airy fairy non information designed to make people believe that they will get there money back. We won't, It is that simple. The money has gone. That sometimes happens when we trade / Invest. Its the nature of the business. As the old platitude goes, you win some you lose some.

[scottdavid70] 27/1/2021 10:48

Just look at LSE celebrating like Covid has vanished into thin air. Thats what these people, these Board members, these Directors who have destroyed the share price now bank on is the ecstasy of something no matter the pittance it will be for especially long term shareholders but also for even medium term those with averages of 1p let alone some who may still be sitting on 20p plus averages.

They are banking on human nature. No patience they have taken this long for a reason, desperation had set it so the relief there maybe something is in the air and palpable. Hope over despair mainly though is the emotional trade they have made here. LSE popping champagne corks

Well I believe there are enough shareholders whom dont want to lose virtually everything to just have to sit and watch Glumsden and Gold ride off into the sunset with in our view unearned money. So they would rather let Lumsden and Gold know what it feels to lose the lot like we have pretty much felt for 2 years

[scottdavid70] 27/1/2021 10:26

That’s what they are banking on - sheer desperation and they win no matter how bad the deal is.

The only way we get a victory even if it’s pyrrhic is by those two not getting their ill gotten bonus and deferred salary. It stinks so bad I am chocking on the aroma

I won’t be voting for it as it stands and no will a lot of us. It’s money we have decided to lose to take a stand against this happening to anyone else plus I hope to recoup my money from the book sales

[moneymunch] 27/1/2021 08:04

Lol...Ye of little faith....time will tell mate, a short time at that. Gl ;-)

[mostro] 27/1/2021 07:44

That RNS is the biggest pile of steaming cack you will ever read in your life!!!

[dafad] 27/1/2021 07:21

or this one

[moneymunch] 27/1/2021 07:19

Could be this one??? ;-)

[moneymunch] 27/1/2021 07:17

All good things......;-)

[georgia103] 27/1/2021 07:11

Nice one Moneymunch

[moneymunch] 27/1/2021 07:07

Ho ho ho ho ;-)

[dafad] 27/1/2021 07:06

hxxp://www.antikor.co.uk/ ????

hxxps://www.spirea.co.uk/ ???

[moneymunch] 27/1/2021 07:05

Ho ho ho ho ho.....Gla ;-)

[moneymunch] 27/1/2021 07:04

RNS Number : 9727M
Motif Bio PLC
27 January 2021






Motif Bio plc

("Motif" or the "Company")



Update re proposed Reverse Takeover



Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, provides a further update regarding the proposed reverse takeover pursuant to AIM Rule 14 ("Reverse Takeover") that was outlined in the Company's announcement of 5 January 2021.



Motif announces that it continues to progress a Reverse Takeover under a Heads of Terms Agreement ("HOT") with a UK based candidate in the healthcare sector (the "Target"), as a result of which, subject to, among other matters, the execution of a Sale and Purchase Agreement (the "SPA"), Motif would acquire the entire issued share capital of the Target (the "Proposed Transaction"). Motif will remain suspended from trading while the Proposed Transaction is negotiated and advanced, and the Company will provide shareholders with further updates as appropriate.



The Target

The Target is a UK-based ADC (Antibody-Drug Conjugate) discovery and development company, which uses front-line clinical experience to develop next generation therapeutics for the treatment of various cancers.



The Proposed Transaction

The Proposed Transaction will be classified as a Reverse Takeover. Completion of the Proposed Transaction is therefore subject to certain matters including the completion of an appropriate SPA, approval by Motif's shareholders at a general meeting to be convened in due course ("General Meeting"), the raising of an appropriate level of equity (the "Fundraising") to accelerate the Target's development programmes, the grant of a Rule 9 waiver by the UK Takeover Panel ("Rule 9 Waiver") in respect of the proposed issue of new shares to the Target and the admission of the enlarged group to trading on AIM.



In order to convene the General Meeting, the Company is required to publish an AIM Admission Document which details, inter alia, the terms of the Proposed Transaction. As per the HOT, consideration for the Proposed Transaction will be paid in ordinary shares of Motif. In addition to the Fundraising, it is intended that the Company will carry out an appropriate share consolidation and that Motif will change its name.



Should the Proposed Transaction proceed, it is currently expected that the AIM Admission Document will be published before the end of March 2021. At present there can be no assurances that Motif will be able to complete the Proposed Transaction and as a consequence the Company's admission to trading on AIM may be cancelled.



The AIM Admission Document will include a Technical Expert's report which is being prepared in respect of the Target's technology and assets.



Jonathan Gold, Motif's President and Chief Business Officer, commented: "The Motif Directors are encouraged by the way the Proposed Transaction is progressing and I look forward to providing our shareholders with further updates and additional information regarding the Target in due course."